Immutep Ltd. Releases INSIGHT-003 Study Results on Eftilagimod Alpha in First-Line Non-Small Cell Lung Cancer
Immutep Ltd. has released updates from its INSIGHT-003 clinical study on eftilagimod alpha, a soluble LAG-3 protein, in combination with first-line chemo-immunotherapy for patients with metastatic non-squamous non-small cell lung cancer. The document details study design, baseline characteristics, safety, tolerability, and efficacy results for the evaluable patient population. The full document is available via a provided link. This news brief is generated by Public Technologies and is for informational purposes only, not financial or legal advice.
Immutep Ltd. published a document detailing updates from a clinical study on eftilagimod alpha (soluble LAG-3 protein) combined with first-line chemo-immunotherapy in patients with metastatic non-squamous non-small cell lung cancer. The document includes information on study design, baseline characteristics, safety and tolerability, as well as efficacy results for the evaluable patient population. The full document can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on October 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
